- Home
- SKK vs BIAF Comparison
SKK vs BIAF Comparison
Compare SKK & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKK
- BIAF
- Stock Information
- Founded
- SKK 2013
- BIAF 2014
- Country
- SKK Singapore
- BIAF United States
- Employees
- SKK N/A
- BIAF N/A
- Industry
- SKK
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SKK
- BIAF Health Care
- Exchange
- SKK NYSE
- BIAF Nasdaq
- Market Cap
- SKK 12.0M
- BIAF 12.2M
- IPO Year
- SKK 2024
- BIAF 2022
- Fundamental
- Price
- SKK $0.58
- BIAF $0.33
- Analyst Decision
- SKK
- BIAF Hold
- Analyst Count
- SKK 0
- BIAF 1
- Target Price
- SKK N/A
- BIAF N/A
- AVG Volume (30 Days)
- SKK 51.4K
- BIAF 2.2M
- Earning Date
- SKK 02-14-2025
- BIAF 08-13-2025
- Dividend Yield
- SKK N/A
- BIAF N/A
- EPS Growth
- SKK 99.13
- BIAF N/A
- EPS
- SKK 0.03
- BIAF N/A
- Revenue
- SKK $11,301,000.00
- BIAF $8,809,228.00
- Revenue This Year
- SKK N/A
- BIAF N/A
- Revenue Next Year
- SKK N/A
- BIAF $20.00
- P/E Ratio
- SKK $20.75
- BIAF N/A
- Revenue Growth
- SKK 15.80
- BIAF 78.40
- 52 Week Low
- SKK $0.53
- BIAF $0.16
- 52 Week High
- SKK $11.45
- BIAF $2.69
- Technical
- Relative Strength Index (RSI)
- SKK N/A
- BIAF 51.97
- Support Level
- SKK N/A
- BIAF $0.31
- Resistance Level
- SKK N/A
- BIAF $0.36
- Average True Range (ATR)
- SKK 0.00
- BIAF 0.03
- MACD
- SKK 0.00
- BIAF -0.00
- Stochastic Oscillator
- SKK 0.00
- BIAF 54.95
About SKK SKK HOLDINGS LIMITED
SKK Holdings Ltd is a civil engineering service provider that specializes in subsurface utility works in Singapore. It construct and maintain various public works and infrastructure projects that serve the society and the environment. Its projects are the subsurface work related to projects undertaken by the Public Utilities Board (PUB) and Singapore Telecommunications Limited. The nature of these projects is related to repairing of pumping mains, sewer maintenance and pipe cable laying.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.